886362-62-5 Usage
Uses
Used in Organic Synthesis:
4-(3-BROMO-PHENYL)-1-N-BOC-PIPERIDINE is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure allows for the formation of new molecules with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(3-BROMO-PHENYL)-1-N-BOC-PIPERIDINE is utilized as an intermediate in the development of new drugs. Its presence in the molecular structure can contribute to the pharmacological properties of the final drug product, making it a valuable component in drug discovery and design.
Used in the Synthesis of Bioactive Molecules:
4-(3-BROMO-PHENYL)-1-N-BOC-PIPERIDINE is employed as a precursor in the synthesis of bioactive molecules. Its chemical properties enable the production of compounds with potential therapeutic effects, contributing to advancements in medicine and healthcare.
Check Digit Verification of cas no
The CAS Registry Mumber 886362-62-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 886362-62:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*2)+(2*6)+(1*2)=215
215 % 10 = 5
So 886362-62-5 is a valid CAS Registry Number.
InChI:InChI=1/C16H22BrNO2/c1-16(2,3)20-15(19)18-9-7-12(8-10-18)13-5-4-6-14(17)11-13/h4-6,11-12H,7-10H2,1-3H3
886362-62-5Relevant academic research and scientific papers
Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors
Bayliss, Tracy,Robinson, David A.,Smith, Victoria C.,Brand, Stephen,McElroy, Stuart P.,Torrie, Leah S.,Mpamhanga, Chido,Norval, Suzanne,Stojanovski, Laste,Brenk, Ruth,Frearson, Julie A.,Read, Kevin D.,Gilbert, Ian H.,Wyatt, Paul G.
supporting information, p. 9790 - 9806 (2017/12/26)
N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stages 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a starting point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.
